The DUSP3 Knockout 786-O Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human 786-O renal cell carcinoma line, engineered to disrupt the endogenous DUSP3 gene. This loss-of-function model enables investigation of DUSP3-dependent regulatory mechanisms within a renal cancer genetic background. The polyclonal population preserves heterogeneous editing events, facilitating studies that require consistent gene knockout without clonal selection artifacts. It serves as a robust tool for functional genomics, pathway dissection, and phenotypic profiling in cancer research.
The parental 786-O cell line originates from a primary clear cell renal adenocarcinoma and carries a well-characterized VHL gene mutation, which is a hallmark of the majority of sporadic clear cell renal cell carcinomas. This VHL deficiency leads to constitutive stabilization of hypoxia-inducible factors (HIFs), driving angiogenesis and metabolic reprogramming. The 786-O line is extensively employed in renal cancer biology to study tumorigenesis, drug resistance, and metastasis, making it an ideal host for interrogating the role of additional tumor suppressors or oncogenes such as DUSP3.
DUSP3 encodes a dual-specificity protein phosphatase that dephosphorylates both tyrosine and serine/threonine residues on key mitogen-activated protein kinases, primarily ERK1/2 (MAPK1/3) and JNK (MAPK8/9). By inactivating these signaling nodes, DUSP3 attenuates MAPK pathway output, thereby modulating transcription of proliferation and survival genes through downstream effectors including ELK1 and c-JUN. DUSP3 activity is regulated by the E2F1 transcription factor and cellular stressors such as oxidative stress and mitogenic signals. It directly interacts with MAPK1 (ERK2) and MAPK8 (JNK1), and functions within a network comprising HRAS, MAP2K1 (MEK1), and the transcription factors JUN and ELK1. In the context of DUSP3 knockout, enhanced and sustained phosphorylation of ERK1/2 and JNK is anticipated, potentially amplifying pro-tumorigenic transcriptional programs.
In 786-O cells, loss of DUSP3 is expected to exacerbate MAPK signaling, which may cooperate with the existing VHL-HIF axis to promote cell proliferation, survival, and invasive behavior. This knockout model is particularly relevant for dissecting the interplay between phosphatase-mediated signal termination and oncogenic drivers in clear cell renal cell carcinoma. Additionally, DUSP3’s role in other solid tumors such as breast and lung cancers broadens the model’s applicability to comparative oncology studies exploring tumor-type-specific dependencies on MAPK regulation.
Researchers can employ DUSP3 Knockout 786-O Polyclonal Cells in a variety of assays, including western blotting for phospho-ERK and total ERK, MTT-based proliferation assays, and Annexin V/PI apoptosis detection. Migration and invasion can be assessed using Transwell chambers, while transcriptomic profiling via RNA-seq and RT?qPCR for MAPK target genes reveals downstream expression changes. These applications support MAPK signaling studies, renal cell carcinoma functional genomics, and drug sensitivity screening. For further details on incorporating this model into your research, please contact Ascent Research.
